{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:12:31Z","timestamp":1760184751364,"version":"build-2065373602"},"reference-count":264,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.hoc.2008.07.005","type":"journal-article","created":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T09:21:01Z","timestamp":1225185661000},"page":"903-940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Indolent Lymphomas Other than Follicular and Marginal Zone Lymphomas"],"prefix":"10.1016","volume":"22","author":[{"given":"Stefan","family":"Peinert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2008.07.005_bib1","series-title":"World Health Organization classification of tumours pathology and genetics of tumours of haematopoietic and lymphoid tissues","first-page":"127","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma","author":"M\u00fcller-Hermelink","year":"2001"},{"issue":"5","key":"10.1016\/j.hoc.2008.07.005_bib2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.1989.7.5.598","article-title":"Small lymphocytic lymphoma","volume":"7","author":"Morrison","year":"1989","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib3","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/1097-0142(197804)41:4<1440::AID-CNCR2820410432>3.0.CO;2-G","article-title":"Malignant lymphoma, small lymphocytic type: a clinicopathologic study of 84 cases with suggested criteria for intermediate lymphocytic lymphoma","volume":"41","author":"Evans","year":"1978","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00000441-200602000-00013","article-title":"Orbital lymphomas: a clinicopathologic study of a rare disease","volume":"331","author":"Ahmed","year":"2006","journal-title":"Am J Med Sci"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00000478-198906000-00002","article-title":"Lymphoid infiltrates of the orbit and conjunctiva. A morphologic and immunophenotypic study of 99 cases","volume":"13","author":"Medeiros","year":"1989","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2005.05550.x","article-title":"Diagnostic criteria for monoclonal B-cell lymphocytosis","volume":"130","author":"Marti","year":"2005","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.005_bib7","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.V73.2.579.579","article-title":"Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases","volume":"73","author":"Ben-Ezra","year":"1989","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib9","first-page":"43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"issue":"29","key":"10.1016\/j.hoc.2008.07.005_bib10","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1200\/JCO.2006.09.4508","article-title":"Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center","volume":"25","author":"Tsimberidou","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1182\/blood.V100.2.635","article-title":"Monoclonal B lymphocytes with the characteristics of \u201cindolent\u201d chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts","volume":"100","author":"Rawstron","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib12","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","volume":"89","author":"The Non-Hodgkin's Lymphoma Classification Project","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.005_bib13","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Non-Hodgkin's Lymphoma Classification Project","volume":"49","year":"1982","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.005_bib14","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/08820130500496878","article-title":"A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry","volume":"35","author":"Olejniczak","year":"2006","journal-title":"Immunol Invest"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib16","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1182\/blood-2003-09-3103","article-title":"Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas","volume":"104","author":"Trentin","year":"2004","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.005_bib17","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1080\/10428190410001723449","article-title":"Chemokine receptor expression in B-cell lymphoproliferative disorders","volume":"45","author":"Wong","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.hoc.2008.07.005_bib18","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood.V95.7.2455","article-title":"Immunoglobulin V genes and CD38 expression in CLL","volume":"95","author":"Hamblin","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2008.07.005_bib19","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2003-11-3890","article-title":"CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow","volume":"103","author":"Jaksic","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib20","first-page":"654","article-title":"Lymphotoxin beta expression is high in chronic lymphocytic leukemia but low in small lymphocytic lymphoma: a quantitative real-time reverse transcriptase polymerase chain reaction analysis","volume":"88","author":"Nagy","year":"2003","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.hoc.2008.07.005_bib21","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin's lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib22","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib23","first-page":"104","article-title":"B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstr\u00f6m's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders","volume":"36","author":"Pangalis","year":"1999","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2005-04-1677","article-title":"Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia","volume":"107","author":"Binet","year":"2006","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2008.07.005_bib27","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib28","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2008.07.005_bib29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2006.08.3089","article-title":"Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997","volume":"25","author":"Grever","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2005.03.1021","article-title":"Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy","volume":"24","author":"Byrd","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib31","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.leu.2403242","article-title":"Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis","volume":"18","author":"Cuneo","year":"2004","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib32","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib33","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"9403","key":"10.1016\/j.hoc.2008.07.005_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(03)15260-9","article-title":"ZAP-70 expression and prognosis in chronic lymphocytic leukaemia","volume":"363","author":"Orchard","year":"2004","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.hoc.2008.07.005_bib35","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib36","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2002-06-1801","article-title":"The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression","volume":"101","author":"Ghia","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-0609.1994.tb00648.x","article-title":"Comparison of younger versus older B-cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases","volume":"52","author":"Molica","year":"1994","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib38","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood.V78.6.1545.1545","article-title":"Presenting features and prognosis of chronic lymphocytic leukemia in younger adults","volume":"78","author":"Montserrat","year":"1991","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2141.1989.tb07674.x","article-title":"Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults","volume":"72","author":"Catovsky","year":"1989","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/bjc.1991.303","article-title":"The roles of age and sex in the prognosis\u00a0of chronic leukaemias. A study of 373 cases","volume":"64","author":"Jaksic","year":"1991","journal-title":"Br J Cancer"},{"issue":"5\u20136","key":"10.1016\/j.hoc.2008.07.005_bib41","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/10428199609054782","article-title":"Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma","volume":"22","author":"Hallek","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2008.07.005_bib42","first-page":"606","article-title":"The serum \u03b22-microglobulin (beta2m) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL)","volume":"86","author":"Keating","year":"1995","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib43","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1200\/JCO.1994.12.10.2146","article-title":"Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia","volume":"12","author":"Reinisch","year":"1994","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2008.07.005_bib44","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia","volume":"353","author":"Calin","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib45","first-page":"750","article-title":"High CD69 protein expression predicts a poor prognosis in B-cell chronic lymphocytic leukemia (B-CLL)","volume":"110","author":"Del Poeta","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib46","first-page":"745","article-title":"Percentage of smudge cells on blood smear predicts prognosis in chronic lymphocytic leukemia: a multicenter study","volume":"110","author":"Nowakowski","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib47","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/1097-0142(19810915)48:6<1415::AID-CNCR2820480625>3.0.CO;2-N","article-title":"Malignant lymphoma, intermediate lymphocytic type: a clinicopathologic study of 42 cases","volume":"48","author":"Weisenburger","year":"1981","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.hoc.2008.07.005_bib48","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199805213382104","article-title":"Chlorambucil in indolent chronic lymphocytic leukemia","volume":"338","author":"Dighiero","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hon.2900060103","article-title":"Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation","volume":"6","author":"Shustik","year":"1988","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib50","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/jnci\/91.10.861","article-title":"Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials","volume":"91","author":"CLL Trialists' Collaborative Group","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib51","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy","volume":"92","author":"Keating","year":"1998","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib52","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1046\/j.1365-2141.2002.03959.x","article-title":"Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia","volume":"119","author":"Bosch","year":"2002","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.hoc.2008.07.005_bib53","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2008.07.005_bib54","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V98.1.29","article-title":"Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy","volume":"98","author":"Rawstron","year":"2001","journal-title":"Blood"},{"year":"1998","series-title":"Effect of combined treatment with 4-hydroperoxycyclophosphamide and fludarabine on cytotoxicity and repair of damaged DNA. Acute leukemias VII: experimental approaches and novel therapies","author":"Koehi","key":"10.1016\/j.hoc.2008.07.005_bib56"},{"issue":"9583","key":"10.1016\/j.hoc.2008.07.005_bib57","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib58","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.005_bib59","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1002\/cncr.20264","article-title":"Fludarabine and mitoxantrone\u00a0for\u00a0patients with chronic lymphocytic leukemia","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib60","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1023\/A:1012551809100","article-title":"Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders","volume":"12","author":"Seymour","year":"2001","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib61","first-page":"926","article-title":"Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients","volume":"87","author":"Mauro","year":"2002","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib62","first-page":"943","article-title":"Fludarabine plus doxorubicin in\u00a0previously treated chronic lymphocytic leukemia","volume":"9","author":"Robertson","year":"1995","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib63","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1008312432416","article-title":"Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study","volume":"10","author":"Rummel","year":"1999","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2008.07.005_bib64","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1200\/JCO.2003.08.100","article-title":"Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia","volume":"21","author":"Weiss","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib65","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2005-12-4828","volume":"108","author":"Robak","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.005_bib66","series-title":"Leucocyte typing v white cell differentiation antigens","first-page":"511","article-title":"CD20 Workshop Panel report","author":"Zhou","year":"1995"},{"issue":"8","key":"10.1016\/j.hoc.2008.07.005_bib67","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2008.07.005_bib68","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O'Brien","year":"2001","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib69","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib70","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","article-title":"Effect of Campath-1H antibody on human hematopoietic progenitors in vitro","volume":"82","author":"Gilleece","year":"1993","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib71","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2008.07.005_bib72","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","article-title":"Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine","volume":"20","author":"Rai","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib73","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cncr.11551","article-title":"Phase II study of alemtuzumab in chronic lymphoproliferative disorders","volume":"98","author":"Ferrajoli","year":"2003","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib74","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","article-title":"Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy","volume":"347","author":"Stilgenbauer","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib75","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions","volume":"103","author":"Lozanski","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib76","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib77","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2002-07-1952","article-title":"Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies","volume":"101","author":"Faderl","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.005_bib78","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1080\/10428190701647879","volume":"48","author":"Cruz","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib79","first-page":"709","article-title":"Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis","volume":"7","author":"Alas","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib80","first-page":"33","article-title":"Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow","year":"2002","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib81","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1046\/j.1365-2141.2001.03014.x","article-title":"Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone","volume":"114","author":"Di Gaetano","year":"2001","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib82","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.beha.2007.02.004","article-title":"Chemoimmunotherapy of chronic lymphocytic leukemia","volume":"20","author":"Tam","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib84","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/cncr.21882","article-title":"Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma","volume":"106","author":"Tam","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2008.07.005_bib85","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.90140.6565","article-title":"Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) improves complete response (CR), remission duration and survival as initial therapy of chronic lymphocytic leukemia (CLL)","volume":"22","author":"Keating","year":"2004","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2008.07.005_bib86","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib87","first-page":"2117","article-title":"FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL)","volume":"106","author":"O'Brien","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.hoc.2008.07.005_bib88","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.6607","article-title":"A phase II study of fludarabine (F), cyclophosphamide (C), and mitoxantrone (M) plus rituximab (R) (FCM-R) in previously untreated patients (pts) with CLL < 70 years (yrs)","volume":"24","author":"Faderl","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib89","first-page":"627","article-title":"Update of experience with fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline therapy for chronic lymphocytic leukemia (CLL)","volume":"110","author":"Faderl","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib90","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","article-title":"Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia","volume":"109","author":"Kay","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib91","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.005_bib92","article-title":"Phase II multicenter trial of pentostatin and rituximab in patients with previously treated and untreated chronic lymphocytic leukemia","volume":"102","author":"Yunus","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib93","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/blood.V99.6.2245","article-title":"Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia","volume":"99","author":"Kennedy","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib94","first-page":"2120","article-title":"Interim report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group)","volume":"106","author":"Sayala","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"28","key":"10.1016\/j.hoc.2008.07.005_bib95","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1200\/JCO.2005.01.9950","article-title":"Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory b-cell chronic lymphocytic leukemia: results of a phase II trial","volume":"23","author":"Elter","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib96","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2005-02-0669","article-title":"Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)","volume":"106","author":"Chanan-Khan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.005_bib97","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.6640","article-title":"Thalidomide alone or in combination with fludarabine are effective treatments for patients with fludarabine-relapsed and refractory CLL","volume":"23","author":"Furman","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib98","first-page":"3124","article-title":"Thalidomide alone and in combination with fludarabine exerts distinct molecular and antileukemic effects in B-cell chronic lymphocytic leukemia","volume":"110","author":"Giannopoulos","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"34","key":"10.1016\/j.hoc.2008.07.005_bib99","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.005_bib100","first-page":"S166","article-title":"Clinical activity of lenalidomide in relapsed or refractory chronic lymphocytic leukemia (CLL) patients: updated results of a phase II clinical trial","volume":"48","author":"Chanan-Khan","year":"2007","journal-title":"Leuk Lymph"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib101","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib102","first-page":"305","article-title":"Lenalidomide induces complete and\u00a0partial responses in patients with relapsed and treatment-refractory chronic\u00a0lymphocytic leukemia (CLL)","volume":"108","author":"Ferrajoli","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib103","first-page":"754","article-title":"Lenalidomide is active in patients with relapsed\/refractory chronic lymphocytic leukemia (CLL) carrying unfavorable\u00a0chromosomal abnormalities","volume":"110","author":"Ferrajoli","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib104","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","article-title":"Lenalidomide for the treatment of B-cell malignancies","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib105","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","article-title":"Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"25","author":"O'Brien","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib106","first-page":"2503","article-title":"Safety and efficacy results from a phase i trial of single-agent lumiliximab (anti-CD23 antibody) for chronic lymphocytic leukemia","volume":"104","author":"Byrd","year":"2004","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib107","first-page":"2842","article-title":"Significant correlation between survival endpoints and exposure to ofatumumab (HuMax-CD20) in chronic lymphocytic leukemia","volume":"108","author":"Coiffier","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib108","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib109","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2003-07-2281","article-title":"Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL","volume":"103","author":"Shanafelt","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib110","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.seminoncol.2006.01.017","article-title":"Risk stratification in chronic lymphocytic leukemia","volume":"33","author":"Seiler","year":"2006","journal-title":"Semin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2008.07.005_bib111","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1182\/blood-2003-05-1549","article-title":"The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status","volume":"103","author":"Dreger","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib112","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1023\/A:1008474526373","article-title":"High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"9","author":"Pavletic","year":"1998","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2008.07.005_bib113","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib114","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2004-01-0298","article-title":"Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses","volume":"105","author":"Milligan","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib115","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood.V82.4.1366.1366","article-title":"Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia","volume":"82","author":"Rabinowe","year":"1993","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib116","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO.1994.12.4.748","article-title":"Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results","volume":"12","author":"Khouri","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.005_bib117","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.bmt.1705375","article-title":"Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience","volume":"37","author":"Jantunen","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib118","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood-2003-05-1449","article-title":"Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia","volume":"103","author":"Tournilhac","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib119","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2141.2000.01900.x","volume":"108","author":"Michallet","year":"2000","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2008.07.005_bib120","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.leu.2403326","article-title":"Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine","volume":"18","author":"Morgan","year":"2004","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib121","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.thj.6200061","article-title":"Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma","volume":"1","author":"Micallef","year":"2000","journal-title":"Hematol J"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib122","first-page":"3066","volume":"108","author":"Seymour","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib123","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/0003-4819-124-3-199602010-00005","article-title":"HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia","volume":"124","author":"Michallet","year":"1996","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib124","doi-asserted-by":"crossref","first-page":"780","DOI":"10.7326\/0003-4819-125-9-199611010-00026","article-title":"Allogeneic bone marrow transplantation in chronic lymphocytic leukemia","volume":"125","author":"Khouri","year":"1996","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib125","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/sj.bmt.1703548","article-title":"Seattle Bone Marrow Transplant Team. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia","volume":"29","author":"Doney","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl I","key":"10.1016\/j.hoc.2008.07.005_bib126","first-page":"96","article-title":"Haemopoietic stem cell transplantation for chronic lymphocytic leukemia","author":"Horowitz","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib127","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.bmt.1705130","article-title":"Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease","volume":"36","author":"Toze","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"10.1016\/j.hoc.2008.07.005_bib128","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","article-title":"Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group","volume":"21","author":"Schetelig","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2008.07.005_bib129","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2402905","article-title":"Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning","volume":"17","author":"Dreger","year":"2003","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.hoc.2008.07.005_bib130","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2005.04.569","article-title":"Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia","volume":"23","author":"Sorror","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.005_bib131","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/asheducation-2006.1.390","article-title":"Reduced-intensity regimens in allogeneic stem-cell transplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia","author":"Khouri","year":"2006","journal-title":"Hematology\/The Education Program of the American Society of Hematology"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib132","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2006.06.004","article-title":"Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia","volume":"12","author":"Brown","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib133","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2005-08-3372","article-title":"Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study","volume":"107","author":"Delgado","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib134","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/sj.leu.2403745","article-title":"Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis","volume":"19","author":"Dreger","year":"2005","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.hoc.2008.07.005_bib135","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1158\/1078-0432.CCR-05-0941","article-title":"Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)","volume":"11","author":"Caballero","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib136","first-page":"1662","article-title":"Long-term follow up of patients (pts) with high-risk chronic lymphocytic leukemia (CLL) given nonmyeloablative allogeneic hematopoietic cell transplantation (HCT)","volume":"110","author":"Sorror","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib137","first-page":"47","article-title":"Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia (CLL) with 17p deletion: a retrospective EBMT analysis","volume":"110","author":"Schetelig","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib138","first-page":"486","article-title":"Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients (Pts) with advanced indolent NHL and CLL: CALGB 109901","volume":"110","author":"Shea","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib139","first-page":"3045","article-title":"Outcomes of hematopoietic stem cell\u00a0transplantation for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL)","volume":"110","author":"Dickinson","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.hoc.2008.07.005_bib140","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.0954-6820.1944.tb03955.x","article-title":"Incipient myelomatosis or \u2018essential\u2019 hyperglobulinemia with fibrinogenemia: a new syndrome?","volume":"117","author":"Waldenstrom","year":"1944","journal-title":"Acta Med Scand"},{"issue":"5","key":"10.1016\/j.hoc.2008.07.005_bib141","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib142","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib143","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V82.10.3148.3148","article-title":"Incidence of Waldenstrom's macroglobulinemia","volume":"82","author":"Herrinton","year":"1993","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib144","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3","article-title":"Waldenstr\u00f6m's macroglobulinemia","volume":"82","author":"Groves","year":"1998","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.2000.18.1.214","article-title":"Waldenstrom's macroglobulinemia: clinical features, complications, and management","volume":"18","author":"Dimopoulos","year":"2000","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2008.07.005_bib146","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.297.18.2010","article-title":"Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus","volume":"297","author":"Giordano","year":"2007","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib147","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000209015","article-title":"Waldenstr\u00f6ms macroglobulinaemia. A family study","volume":"38","author":"Brown","year":"1967","journal-title":"Acta Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib148","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3816\/CLM.2005.n.005","article-title":"Cytogenetics of familial Waldenstrom's macroglobulinemia: in pursuit of an understanding of genetic predisposition","volume":"5","author":"McMaster","year":"2005","journal-title":"Clin Lymphoma"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib149","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1086\/507687","article-title":"Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families","volume":"79","author":"McMaster","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib150","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/annonc\/mdj111","article-title":"Characterization of familial Waldenstrom's macroglobulinemia","volume":"17","author":"Treon","year":"2006","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2008.07.005_bib151","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1158\/1078-0432.CCR-07-0299","article-title":"Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families","volume":"13","author":"McMaster","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib152","first-page":"1363","article-title":"A case-control and family study of Waldenstrom's macroglobulinemia","volume":"7","author":"Linet","year":"1993","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2008.07.005_bib153","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2008.07.005_bib154","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/jnci\/22.5.887","article-title":"The histopathology of the macroglobulinemia of Waldenstr\u00f6m","volume":"22","author":"Dutcher","year":"1959","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2141.1987.tb04139.x","article-title":"Analysis of leucocyte differentiation antigens in blood and bone marrow from patients with Waldenstr\u00f6m's macroglobulinaemia","volume":"65","author":"Kucharska-Pulczynska","year":"1987","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2008.07.005_bib156","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/annonc\/mdl109","article-title":"Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154\/CD40 signaling","volume":"17","author":"Tournilhac","year":"2006","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2008.07.005_bib157","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2005-09-3552","article-title":"B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia","volume":"107","author":"Elsawa","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2008.07.005_bib158","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.pap.0000184176.65919.17","article-title":"Lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia: an evolving concept","volume":"12","author":"Lin","year":"2005","journal-title":"Adv Anat Pathol"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib159","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1309\/3G1XDX0DVHBNVKB4","article-title":"Immunophenotypic profile of lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia","volume":"124","author":"Konoplev","year":"2005","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib160","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/sonc.2003.50073","article-title":"Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells","volume":"30","author":"Remstein","year":"2005","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib161","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/sonc.2003.50074","article-title":"Immunophenotypic analysis of Waldenstrom's macroglobulinemia","volume":"30","author":"San Miguel","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hoc.2008.07.005_bib162","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-04-084525","article-title":"CD27\u2013CD70 interactions in the pathogenesis of Waldenstrom's macroglobulinemia","author":"Ho","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.005_bib163","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1182\/blood.V83.12.3647.3647","article-title":"Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma","volume":"83","author":"Wagner","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib164","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V91.1.238","article-title":"VH gene analysis of clonally related IgM and IgG from human lymphoplasmacytoid B-cell tumors with chronic lymphocytic leukemia features and high serum monoclonal IgG","volume":"91","author":"Sahota","year":"1998","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib165","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3816\/CLM.2005.n.002","article-title":"Origins of Waldenstrom's macroglobulinemia: does it arise from an unusual B-cell precursor?","volume":"5","author":"Kriangkum","year":"2005","journal-title":"Clin Lymphoma"},{"issue":"7","key":"10.1016\/j.hoc.2008.07.005_bib166","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1158\/1078-0432.CCR-06-2788","article-title":"Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences","volume":"13","author":"Kriangkum","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2008.07.005_bib167","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-09-3613","article-title":"Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery","volume":"107","author":"Kriangkum","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib168","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1365-2141.2006.06397.x","article-title":"Functional class switch recombination may occur \u2018in vivo\u2019 in Waldenstr\u00f6m macroglobulinaemia","volume":"136","author":"Martin-Jimenez","year":"2007","journal-title":"Br J\u00a0Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib169","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000130783","article-title":"Marker chromosome of macroglobulinemia identified by G-banding","volume":"18","author":"Contrafatto","year":"1977","journal-title":"Cytogenet Cell Genet"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib170","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.V62.3.525.525","article-title":"Clonal chromosome abnormalities in patients with Waldenstrom's and CLL-associated macroglobulinemia: significance of trisomy 12","volume":"62","author":"Han","year":"1983","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2008.07.005_bib171","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood.V100.8.2996","article-title":"Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions","volume":"100","author":"Schop RFJ","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib172","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1309\/6U88-357U-UKJ5-YPT3","article-title":"Cytogenetic findings in lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course","volume":"116","author":"Mansoor","year":"2001","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib173","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0165-4608(98)00223-4","article-title":"Multiple karyotypic aberrations in a polymorphous variant of Waldenstrom macroglobulinemia","volume":"111","author":"Jankovic","year":"1999","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib174","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0165-4608(00)00334-4","article-title":"Waldenstrom macroglobulinemia with karyotypic aberrations involving both homologous 6q","volume":"124","author":"Wong","year":"2001","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib175","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2006.06389.x","article-title":"6q deletion in Waldenstr\u00f6m macroglobulinemia is associated with features of adverse prognosis","volume":"136","author":"Ocio","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib176","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0609.2007.00903.x","article-title":"Analysis of 6q deletion in Waldenstrom macroglobulinemia","volume":"79","author":"Chang","year":"2007","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib177","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0165-4608(01)00526-X","article-title":"Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression","volume":"132","author":"Schop","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0609.2001.00152.x","article-title":"Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenstr\u00f6m's macroglobulinemia","volume":"66","author":"Hatzimichael","year":"2001","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib179","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.leu.2404520","article-title":"Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals","volume":"21","author":"Gutierrez","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib180","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2003-03-0801","article-title":"Long-term follow-up of IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Kyle","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2008.07.005_bib181","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1078-0432.CCR-04-1899","article-title":"Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?","volume":"11","author":"Gobbi","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib182","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/088506669501000304","article-title":"Hyperviscosity syndrome","volume":"10","author":"Gertz","year":"1995","journal-title":"J Intensive Care Med"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib183","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.V98.1.41","article-title":"Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)","volume":"98","author":"Dhodapkar","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib184","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2141.2001.03144.x","article-title":"Waldenstr\u00f6m macroglobulinaemia: presenting features and outcome in a series with 217 cases","volume":"115","author":"Garcia-Sanz","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2008.07.005_bib185","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0025-6196(12)65225-2","article-title":"The spectrum of IgM monoclonal gammopathy in 430 cases","volume":"62","author":"Kyle","year":"1987","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib186","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ajcp\/75.1.1","article-title":"IgM myeloma, a distinct entity in the spectrum of B-cell neoplasia","volume":"75","author":"Zarrabi","year":"1981","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib187","first-page":"1553","article-title":"IgM myeloma\u2014its distinction from Waldenstr\u00f6m's macroglobulinemia","volume":"36","author":"Takahashi","year":"1986","journal-title":"Acta Pathol Jpn"},{"issue":"5","key":"10.1016\/j.hoc.2008.07.005_bib188","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1600-0609.1999.tb01144.x","article-title":"IgM myeloma: different features from multiple myeloma and macroglobulinaemia","volume":"63","author":"Kondo","year":"1999","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2008.07.005_bib189","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.1993.11.8.1553","article-title":"Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases","volume":"11","author":"Facon","year":"1993","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib190","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1172\/JCI116178","article-title":"Increased plasma viscosity as a reason for inappropriate erythropoietin formation","volume":"91","author":"Singh","year":"1993","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib191","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10238-004-0025-4","article-title":"Waldenstr\u00f6m's macroglobulinemia: prognostic factors and recent therapeutic advances","volume":"3","author":"Leblond","year":"2004","journal-title":"Clin Exp Med"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib192","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood.V49.2.301.301","article-title":"Blood volume in monoclonal gammopathy","volume":"49","author":"Alexanian","year":"1977","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib193","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V49.4.507.507","article-title":"Blood viscosity in Waldenstrom macroglobulinemia","volume":"49","author":"MacKenzie","year":"1977","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib194","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/00325481.1980.11715533","article-title":"Paraprotein-induced hyperviscosity. A reversible cause of stroke","volume":"68","author":"Pavy","year":"1980","journal-title":"Postgrad Med"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib195","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1212\/WNL.33.1.101","article-title":"Hyperviscosity-induced dementia","volume":"33","author":"Mueller","year":"1983","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib196","first-page":"161","article-title":"Hyperviscosity in diabetic retinopathy treated with Doxium (calcium dobesilate)","volume":"9","author":"Barras","year":"1980","journal-title":"Vasa"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib197","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.35.4.603","article-title":"Waldenstr\u00f6m's macroglobulinemia and peripheral neuropathy: deposition of M-component and kappa light chain in the endoneurium","volume":"35","author":"Vital","year":"1985","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.hoc.2008.07.005_bib198","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199805283382207","article-title":"Neuropathies associated with paraproteinemia","volume":"338","author":"Ropper","year":"1998","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib199","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood.V62.2.280.280","article-title":"Waldenstrom's macroglobulinemia and peripheral neuropathy: a clinical and immunologic study of 25 patients","volume":"62","author":"Dellagi","year":"1983","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib200","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/WNL.37.9.1506","article-title":"Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins","volume":"37","author":"Nobile-Orazio","year":"1987","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.hoc.2008.07.005_bib201","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1200\/JCO.1993.11.5.914","article-title":"Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglobulinemia","volume":"11","author":"Gertz","year":"1993","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib202","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.beha.2005.01.030","article-title":"Amyloidosis","volume":"18","author":"Gertz","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib203","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/sonc.2003.50060","article-title":"Amyloidosis with IgM monoclonal gammopathies","volume":"30","author":"Gertz","year":"2003","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib204","first-page":"852","article-title":"Prognostic factors in Waldenstrom macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients","volume":"96","author":"Morel","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib205","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2006.06003.x","article-title":"Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia","volume":"133","author":"Ghobrial","year":"2006","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.005_bib206","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00277-001-0385-8","article-title":"Waldenstr\u00f6m's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit","volume":"80","author":"Kyrtsonis","year":"2001","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib207","first-page":"279","article-title":"Advanced Waldenstrom's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis","volume":"90","author":"Levy","year":"2005","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib208","first-page":"127","article-title":"International prognostic scoring system (IPSS) for Waldenstrom's macroglobulinemia (WM)","volume":"108","author":"Morel","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib209","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/sonc.2003.50051","article-title":"Asymptomatic Waldenstrom's macroglobulinemia","volume":"30","author":"Alexanian","year":"2003","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib210","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1182\/blood-2005-02-0833","article-title":"Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia","volume":"107","author":"Treon","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib211","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3816\/CLM.2005.n.020","article-title":"Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders","volume":"5","author":"Johnson","year":"2005","journal-title":"Clin Lymphoma"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib212","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2141.2000.01918.x","article-title":"Waldenstr\u00f6m's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil","volume":"108","author":"Kyle","year":"2000","journal-title":"Br J\u00a0Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib213","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0609.1973.tb00031.x","article-title":"Erythroleukaemia in a melphalan-treated patient with primary macroglobulinaemia","volume":"10","author":"Petersen","year":"1973","journal-title":"Scand J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2008.07.005_bib214","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/0002-9343(74)90859-6","article-title":"Development of acute erythroleukemia in B-cell immunoproliferative disorders after prolonged therapy with alkylating drugs","volume":"57","author":"Cardamone","year":"1974","journal-title":"Am J Med"},{"issue":"1\u20132","key":"10.1016\/j.hoc.2008.07.005_bib215","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/10428199909145966","article-title":"Induction of complete haematological remission after monotherapy with anti-CD20 monoclonal antibody (RITUXIMAB) in a patient with alkylating agent resistant Waldenstr\u00f6m's macroglobulinaemia","volume":"36","author":"Weide","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib216","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1046\/j.1365-2141.2000.02086.x","article-title":"The polyneuropathy associated with Waldenstr\u00f6m's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab","volume":"109","author":"Weide","year":"2000","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.005_bib217","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1023\/A:1008350208019","article-title":"Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity","volume":"10","author":"Byrd","year":"1999","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib218","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00002371-200105000-00012","article-title":"CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia","volume":"24","author":"Treon","year":"2001","journal-title":"J Immunother"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib219","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstrom's macroglobulinemia with rituximab","volume":"20","author":"Dimopoulos","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib220","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/annonc\/mdi022","article-title":"Extended rituximab therapy in Waldenstrom's macroglobulinemia","volume":"16","author":"Treon","year":"2005","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib221","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera(R))","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib222","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/annonc\/mdh403","article-title":"Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia","volume":"15","author":"Treon","year":"2004","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib223","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/cncr.20658","article-title":"Initial immunoglobulin M \u2018flare\u2019 after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia","volume":"101","author":"Ghobrial","year":"2004","journal-title":"Cancer"},{"issue":"18S","key":"10.1016\/j.hoc.2008.07.005_bib224","article-title":"Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: results of WMCTG trial 02-079","volume":"24","author":"Hunter","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib225","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3816\/CLM.2005.n.016","article-title":"CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment","volume":"5","author":"Owen","year":"2005","journal-title":"Clin Lymphoma"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib226","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","article-title":"Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstr\u00f6m's macroglobulinemia, and mantle-cell lymphoma","volume":"17","author":"Foran","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib227","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s002770000185","article-title":"Fludarabine therapy in Waldenstr\u00f6m's macroglobulinemia","volume":"79","author":"Thalhammer-Scherrer","year":"2000","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib228","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-118-3-199302010-00007","article-title":"Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine","volume":"118","author":"Dimopoulos","year":"1993","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.005_bib229","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1200\/JCO.1994.12.12.2694","article-title":"Primary therapy of Waldenstr\u00f6m's macroglobulinemia with 2-chlorodeoxyadenosine","volume":"12","author":"Dimopoulos","year":"1994","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib230","first-page":"317","article-title":"2-Chlorodeoxyadenosine therapy in Waldenstrom's macroglobulinaemia","volume":"36","author":"Delannoy","year":"1994","journal-title":"Nouv Rev Fr Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib231","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s002770050247","article-title":"First-line treatment of Waldenstr\u00f6m's disease with cladribine. Arbeitsgemeinschaft Medikament\u00f6se Tumortherapie","volume":"74","author":"Fridrik","year":"1997","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib232","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0609.1999.tb01848.x","article-title":"Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstr\u00f6m's macroglobulinemia","volume":"63","author":"Hellmann","year":"1999","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib233","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/sonc.2003.50037","article-title":"Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Weber","year":"2003","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib234","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood.V98.9.2640","article-title":"Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstr\u00f6m macroglobulinemia in first relapse or with primary refractory disease","volume":"98","author":"Leblond","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2008.07.005_bib235","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/oxfordjournals.annonc.a059040","article-title":"Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors","volume":"6","author":"Dimopoulos","year":"1995","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib236","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1046\/j.1365-2141.1997.3923206.x","article-title":"Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenstr\u00f6m's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK)","volume":"99","author":"Betticher","year":"1997","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2008.07.005_bib237","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2005.03.144","article-title":"Diagnosis and management of Waldenstrom's macroglobulinemia","volume":"23","author":"Dimopoulos","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib238","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood.V83.10.2906.2906","article-title":"2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia","volume":"83","author":"Seymour","year":"1994","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2008.07.005_bib239","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1200\/JCO.1995.13.9.2431","article-title":"Infectious and immunosuppressive complications of purine analog therapy","volume":"13","author":"Cheson","year":"1995","journal-title":"J Clin Oncol"},{"issue":"5-6","key":"10.1016\/j.hoc.2008.07.005_bib240","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3109\/10428199509059649","article-title":"Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas","volume":"18","author":"Fenchel","year":"1995","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib241","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1365-2141.1998.01069.x","article-title":"Bolus administration of cladribine in the treatment of Waldenstr\u00f6m macroglobulinaemia","volume":"103","author":"Liu","year":"1998","journal-title":"Br J Haematol"},{"issue":"7-8","key":"10.1016\/j.hoc.2008.07.005_bib242","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/sj.bjc.6690195","article-title":"Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies","volume":"79","author":"Laurencet","year":"1999","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib243","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/sj.leu.2401783","article-title":"Phase I\/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma","volume":"14","author":"Van Den Neste","year":"2000","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.hoc.2008.07.005_bib244","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/sj.leu.2403885","article-title":"Fludarabine plus cyclophosphamide in Waldenstr\u00f6m's macroglobulinemia: results in 49 patients","volume":"19","author":"Tamburini","year":"2005","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib245","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3816\/CLM.2005.n.039","article-title":"Pentostatin\/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia\/lymphoplasmacytic lymphoma","volume":"6","author":"Hensel","year":"2005","journal-title":"Clin Lymphoma Myeloma"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib246","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3816\/CLM.2005.n.040","article-title":"Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstr\u00f6m's macroglobulinemia","volume":"6","author":"Tam","year":"2005","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.hoc.2008.07.005_bib247","unstructured":"Peinert S, Tam CS, Prince HM, et\u00a0al. Fludarabine based combinations are highly effective and safe as first-line or salvage treatment for patients with Waldenstr\u00f6m's macroglobulinemia. Accepted for publication."},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib248","first-page":"1290","article-title":"Fludarabine, cyclophosphamide and rituximab in Waldenstrom's macroglobulinemia: an effective regimen requiring a new category of response criteria and a delayed assessment of results","volume":"110","author":"Tedeschi","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib249","first-page":"4727","article-title":"Fludarabine plus cyclophosphamide and rituximab (RFC) in Waldenstrom's macroglobulinemia (WM): results in 21 patients (pts)","volume":"108","author":"Vargaftig","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"4","key":"10.1016\/j.hoc.2008.07.005_bib250","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3816\/CLM.2005.n.015","article-title":"CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia","volume":"5","author":"Treon","year":"2005","journal-title":"Clin Lymphoma"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib251","first-page":"3616","article-title":"Phase II pilot study of rituximab + CHOP in patients with newly diagnosed Waldenstrom's macroglobulinemia, an Eastern Cooperative Oncology Group Trial (Study E1A02)","volume":"110","author":"Abonour","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib252","first-page":"3015","article-title":"Hematopoietic stem cell transplantation (HSCT) in Waldenstrom macroglobulinemia (WM), update of the French experience in 54 cases","volume":"110","author":"Dhedin","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib253","first-page":"941","article-title":"The role of autologous stem cell transplantation (ASCT) in patients with advanced Waldenstrom's macroglobulinemia","volume":"110","author":"Kyriakou","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib254","first-page":"619","article-title":"Allogeneic stem cell transplantation (allo-SCT) in the management of advanced Waldenstrom's macroglobulinemia (WM)","volume":"110","author":"Kyriakou","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"12","key":"10.1016\/j.hoc.2008.07.005_bib255","first-page":"1655","article-title":"Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib","volume":"90","author":"Dimopoulos","year":"2005","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib256","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1158\/1078-0432.CCR-06-2511","article-title":"Multicenter clinical trial of bortezomib in relapsed\/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248","volume":"13","author":"Treon","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib257","first-page":"4494","article-title":"Phase II trial of combination of bortezomib and rituximab in relapsed and\/or refractory Waldenstrom macroglobulinemia: preliminary results","volume":"110","author":"Ghobrial","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1016\/j.hoc.2008.07.005_bib258","first-page":"2765","article-title":"Bortezomib, dexamethasone and rituximab (BDR) is a highly active regimen in the primary therapy of Waldenstrom's macroglobulinemia: planned interim results of WMCTG clinical trial 05-180","volume":"108","author":"Treon","year":"2006","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"16","key":"10.1016\/j.hoc.2008.07.005_bib259","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1200\/JCO.2001.19.16.3596","article-title":"Treatment of Waldenstrom's macroglobulinemia with thalidomide","volume":"19","author":"Dimopoulos","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib260","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/sonc.2003.50079","article-title":"Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone","volume":"30","author":"Dimopoulos","year":"2003","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2008.07.005_bib261","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1526-0968.2001.00301.x","article-title":"Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinemias","volume":"5","author":"Kaplan","year":"2001","journal-title":"Ther Apher"},{"issue":"2","key":"10.1016\/j.hoc.2008.07.005_bib262","first-page":"135","article-title":"Plasma exchange in the long-term management of Waldenstr\u00f6m's macroglobulinemia","volume":"117","author":"Buskard","year":"1977","journal-title":"Can Med Assoc J"},{"issue":"6","key":"10.1016\/j.hoc.2008.07.005_bib263","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/1097-0142(19870915)60:6<1341::AID-CNCR2820600630>3.0.CO;2-I","article-title":"Cutaneous Waldenstr\u00f6m's macroglobulinemia. A report of a case successfully treated with radiotherapy","volume":"60","author":"Orengo","year":"1987","journal-title":"Cancer"},{"issue":"5 Pt 2","key":"10.1016\/j.hoc.2008.07.005_bib264","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0190-9622(98)70466-9","article-title":"Cutaneous lymphoplasmacytic lymphoma","volume":"38","author":"Allbritton","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2008.07.005_bib265","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/01.iop.0000235814.03599.72","article-title":"Lymphoplasmacytic lymphoma isolated to an extraocular muscle","volume":"22","author":"Malik","year":"2006","journal-title":"Ophthal Plast Reconstr Surg"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858808001032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858808001032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:52:48Z","timestamp":1760183568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858808001032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":264,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0889858808001032"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2008.07.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indolent Lymphomas Other than Follicular and Marginal Zone Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2008.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2008 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}